DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Risk
adverse effects and public
acceptance of, 10
environmental, assessment and
management of, 1853–1855
Risperidone
arrhythmias caused by, 832
dosage of, 426t
metabolism of, 433t
pharmacokinetics of, 1884t
potencies at neurotransmitter
receptors, 427t
side effects of, 426t
Ritodrine, 294
selective β 2
, 1848
structure of, 279t, 292f
Ritonavir, 1626t
ABC transporters and, 105t
absorption of, 1649
antiviral activity of, 1649
chemistry of, 1649
as CYP3A4 inhibitor, 1650
distribution of, 1649
drug interactions with, 1650
elimination of, 1649
mechanism of action of, 1649
pharmacokinetics of, 1884t
precautions with, 1650
structure of, 1648f
therapeutic uses of, 1650
untoward effects of, 1649–1650
RITUXAN (rituximab), 1745
Rituximab, 994t, 1745, 1746t
dosage and administration of, 1747t
dosing, 1746–1747
pharmacokinetics of, 1746
pharmacology of, 1745–1746
resistance to, 1747
therapeutic uses of, 1746
toxicity of, 1747, 1747t
Rivaroxaban, 866
Rivastigmine
for Alzheimer’s, 253
pharmacokinetics of, 1885t
structure of, 243f
River blindness, 1447
Rizatriptan, 345–347
pharmacokinetics of, 1885t
RLS. See Restless leg syndrome (RLS)
ROCEPHIN (ceftriaxone), 1494t, 1496t
Rocker switch mechanism, in
transporters, 101f
Rocuronium
characteristics of, 264t
dosing of, 265t
structure of, 259f
Rodenticides, 860
Rofecoxib, 964–965, 992
in cancer prevention, 972–973
COX isoform selectivity, 962f
pharmacology of, 962f
plasma pharmacokinetics of, 962f
ROFERON A (interferon), 1596t
ROGAINE (minoxidil), 1829
ROLAIDS, 1316t
ROLOFYLLINE (KW-3902), 793
Romiplostim, 1076
RONDEC (carbinoxamine maleate),
921t
Ropinirole
dosage of, 614t
pharmacokinetics of, 1885t
therapeutic uses of, for
parkinsonism, 614t
Ropivacaine, 574
Rosiglitazone,1260–1261
effects on ovulation and fertility,
1845
pharmacokinetics of, 1885t
Rosuvastatin, 893
ABC transporters and, 106t
absorption, fate, and excretion of,
896
chemistry of, 894
dosage of, required to achieve
reduction in LDL-C, 895t
pharmacokinetics of, 1886t
structure of, 893f
therapeutic uses of, 897
Roundworms, 1444–1447
Routes of administration, 20–23, 20t
bioequivalence and, 23
RSD1227 (vernakalant), 845
RU 58668, 1759
Rufinamide, 602–603
RU 486 (mifepristone), in therapeutic
abortion, 952
RU-486 (mifepristone), for pregnancy
termination, 1837
RXR. See Retinoid X receptor (RXR);
Retinoid X receptors
Ryanodine receptor polymorphism,
160t
Ryanodine receptor (RyR), and cardiac
electrophysiology, 818
RYTHMOL (propafenone), 843
S
S-8307, 736
S-8308, 736
SA. See Sinoatrial (SA) node
SABRIL (vigabatrin), 1792
S-adenosyl-methionine (SAM),
138–139
Safety
complexity of concept, 10
determination of, 9–10
metabolism and, 139–142
testing, 78–79, 142
St. John’s wort, 130
Sales, pharmaceutical, 12–13
Salicylates, 977–982
absorption, 978
and acid-base balance, 980
adverse effects and side effects of,
979–981
cardiovascular effects of, 980
chemistry of, 977
classification of, 966t
distribution of, 978
drug interactions with, 981
effects on blood, 980
and electrolyte balance, 980
elimination, 978
endocrine effects of, 980
gastrointestinal effects of, 980
hepatic effects of, 980
hypoglycemia and, 1248t
intoxication/poisoning, 981–982
and acid-base balance, 981–982
cardiovascular effects of, 982
and electrolyte balance, 981–982
endocrine effects of, 982
management of, 982
metabolic effects of, 982
neurological effects of, 981
respiratory effects of, 981
local irritant effects of, 981
mechanism of action of, 977–978
ototoxicity, 980–981
overdose, management of, 982
plasma levels, monitoring, 978–979
and pregnancy, 981
renal effects of, 980
respiratory effects of, 979–980
structure of, 977f
in sunscreen, 1827
therapeutic uses of, 979
local, 979
systemic, 979
uricosuric effects of, 980
Salicylate toxidrome, 83t
Salicylic acid, 102t, 1589, 1829
structure of, 977f
Salicylism, 1829
Saline laxatives, 1331–1332
Saliva, excretion of drugs and,
26–27
2069
INDEX